ArticleNature chemical biology2011
Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine.
Article in Nature chemical biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 93 citations in OpenAlex.
- Non-Canonical Amino Acids in Analyses of Protease Structure and Function.International journal of molecular sciences · 2023Review
- Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.Signal transduction and targeted therapy · 2023Review
- Controlled Protein Activities with Viral Proteases, Antiviral Peptides, and Antiviral Drugs.ACS chemical biology · 2023Article
- Article
- Monomerization of Homodimeric Trefoil Factor 3 (TFF3) by an Aminonitrile Compound Inhibits TFF3-Dependent Cancer Cell Survival.ACS pharmacology & translational science · 2022Article
- Inhibiting a dynamic viral protease by targeting a non-catalytic cysteine.Cell chemical biology · 2022Article
- Identification of Potential Drug Targets of Broad-Spectrum Inhibitors with a Michael Acceptor Moiety Using Shotgun Proteomics.Viruses · 2021Review
- Investigation of some benzoquinazoline and quinazoline derivatives as novel inhibitors of HCV-NS3/4A protease: biological, molecular docking and QSAR studies.RSC advances · 2020Article
- Covalent inhibitors: a rational approach to drug discovery.RSC medicinal chemistry · 2020Review
- Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease.Journal of advanced research · 2020Article
- Delving into the Characteristic Features of "Menace" Mycobacterium tuberculosis Homologs: A Structural Dynamics and Proteomics Perspectives.The protein journal · 2020Article
- Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective.The protein journal · 2020Review
- Targeting HCV polymerase: a structural and dynamic perspective into the mechanism of selective covalent inhibition.RSC advances · 2018Article
- Structural and functional determination of homologs of theThe Journal of biological chemistry · 2018Article
- Current Strategies and Applications for Precision Drug Design.Frontiers in pharmacology · 2018Review
- Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors.The protein journal · 2017Review
- Covalent inhibition of protein tyrosine phosphatases.Molecular bioSystems · 2017Review
- Discovery of host-targeted covalent inhibitors of dengue virus.Antiviral research · 2017Article
- Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions.Journal of medicinal chemistry · 2017Article
- Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery.Current topics in medicinal chemistry · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Designing selective inhibitors of proteases has proven problematic, in part because pharmacophores that confer potency exploit the conserved catalytic apparatus. We developed a fundamentally different approach by designing irreversible inhibitors that target noncatalytic cysteines that are structurally unique to a target in a protein family. We have successfully applied this approach to the important therapeutic target HCV protease, which has broad implications for the design of other selective protease inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.